Indicaciones para el uso de pertuzumab en cáncer de mama HER2 positivono metastásico en los escenarios neoadyuvante y adyuvante. Revisión de la evidencia y abordaje terapéutico en el Instituto Nacional de Cancerología - Colombia / Indications for the use of pertuzumab in non-metastatic HER2-positive breast cancer in the neoadjuvant and adjuvant. Review of the literature and therapeutic approach at the Instituto Nacional de Cancerología - Colombia

La adición de la terapia dirigida a la quimioterapia citotóxica en pacientes con cáncer de mama ha mejorado significativamente los desenlaces oncológicos en las pacientes con tumores HER2 positivo. El uso de pertuzumab durante el manejo neoadyuvante incrementa significativamente la respuesta patológica completa y en la actualidad permite emplear regímenes libres de antraciclinas con una eficacia similar y menores efectos cardiovasculares (en especial sobre la fracción de eyección). El beneficio en supervivencia libre de enfermedad invasiva, de adicionar pertuzumab en el escenario adyuvante en las pacientes sin tratamiento anti HER2 previo, está limitado a aquellas con ganglios positivos. La implementación de esquemas con bloqueo dual anti HER2, durante el tratamiento inicial del cáncer de mama HER2 positivo, mejora significativamente el pronóstico oncológico en este grupo de pacientes.

The addition of targeted therapy to cytotoxic chemotherapy in patients with breast cancer has significantly improved oncologic outcomes in patients with HER2-positive tumors. The use of pertuzumab during neoadjuvant management significantly increases the complete pathological response and currently allows the use of anthracycline-free regimens with similar efficacy and fewer cardiovascular effects (especially on ejection fraction). The benefit of pertuzumab in disease-free survival in the adjuvant setting for patients without prior anti-HER2 treatment is limited to those with positive nodes. The implementation of schemes with dual anti-HER2 blockade during the initial treatment of HER2-positive breast cancer significantly improves the oncological outcomes in this group of patients.

Detección por citometría de flujo de la enfermedad mínima residual en las leucemias agudas / Detection of the minimal residual disease by flow cytometry in patients with acute leukemia

Introducción: La enfermedad mínima residual es la permanencia de células leucémicas residuales en niveles subclínicos luego de la remisión de la enfermedad. Esta condición incrementa el riesgo de recaída y mortalidad. Objetivo: Caracterizar factores clínicos y moleculares de pacientes con leucemias agudas y enfermedad mínima residual detectada por citometría de flujo en una institución de alta complejidad de la ciudad de Medellín, Colombia durante los años 2015 - 2017. Metodología: Este es un estudio descriptivo retrospectivo, que incluyó pacientes con leucemia diagnosticada por citometría de flujo. Se realizó un muestreo no probabilístico de casos consecutivos. La información recolectada fue digitada en una base de datos en Excel, y el análisis se realizó a través del programa IBM SPSS Versión 24, empleando según la naturaleza de cada variable frecuencias absolutas y relativas, promedio y desviación estándar o mediana y rangos intercuartílicos según su distribución. Resultados: Se incluyó un total de 60 pacientes con predominio del sexo masculino 63,3 por ciento (38). El diagnóstico más frecuente fue la leucemia linfoide 78,3 por ciento (47). Del total de pacientes incluidos, 36,6 por ciento (22) fue positivo para enfermedad mínima residual; 28,3 por ciento recibió trasplante de médula ósea y el 10 por ciento (6) presentó compromiso de líquido cefalorraquídeo. En la segunda citometría en pacientes con enfermedad mínima residual, 90,9 por ciento (20) expresaba CD45+. El 31,8 por ciento (7) de los pacientes con enfermedad mínima residual presentó recaída. Conclusión: La enfermedad mínima residual es una condición frecuente en pacientes con leucemias agudas que requiere seguimiento y constituye un factor pronóstico relevante(AU)

Introduction: The minimal residual disease is the permanence of residual leukemic cells at subclinical levels after remission of the disease. This condition increases the risk of relapse and mortality. Objective: To characterize the clinical and molecular factors of patients with acute leukemias and minimal residual disease detected by flow cytometry in a highly complex institution in the city of Medellín, Colombia during the years 2015 - 2017. Methodology: This is a retrospective descriptive observational study, which included patients with leukemia diagnosed by flow cytometry. A non-probabilistic sampling of consecutive cases was carried out. The information collected was entered into a database in Excel, and the analysis was carried out through the IBM SPSS Version 24 program, using absolute and relative frequencies, average and standard deviation or median and interquartile ranges, according to the nature of each variable and its distribution. Results: 60 patients were included in which male sex predominated with 63.3 percent (38). The most frequent diagnosis was lymphoid leukemia with 78.3 percent (47). Of the total patients included, 36.6 percent (22) were positive for minimal residual disease; 28.3 percent received a bone marrow transplant and 10 percent (6) had a cerebrospinal fluid compromise. In the second cytometry of the patients with minimal residual disease, 90.9 percent (20) expressed CD45 +. 31.8 percent (7) of the patients with minimal residual disease relapsed. Conclusion: Minimal residual disease is a frequent pathology in patients with acute leukemias that requires follow-up and constitutes a relevant prognostic factor(AU)

Complicaciones de la linfadenectomía retroperitoneal postquimioterapia en pacientes con tumor germinal de origen testicular: Experiencia de 12 años en un centro de referencia en Colombia / Post-chemotherapy Retroperitoneal Lymphadenectomy Complications in Patients with Testicular Germ Cell Tumors: 12-Year Experience at a Reference Center in Colombia

Objetivo El objetivo de este estudio, fue describir las complicaciones intraoperatorias y postoperatorias, así como la necesidad de cirugías concomitantes en la linfadenectomía retroperitoneal postquimioterapia en un centro de referencia de manejo de cáncer. Métodos Se recolectaron datos de una cohorte retrospectiva de pacientes con diagnóstico de tumor germinal de origen testicular que hubiesen recibido quimioterapia y en quienes se documentó tumor residual retroperitoneal y fueron sometidos a LRP-PC durante 12 años en un centro de referencia de manejo de cáncer. Resultados Se practicó LRP-PC a 64 pacientes. La edad promedio al momento de la cirugía fue 28,1 años (18-47 años). El tamaño promedio de la masa retroperitoneal post quimioterapia fue 6,7 (1­28 cm). La estancia hospitalaria promedio fue 7,9 días (rango 1-99 días), la tasa de cirugías adicionales fue del 20%. La tasa de complicaciones mayores fue de 7,8%. Tener seminoma en la histología testicular inicial se asoció con un mayor sangrado y el tamaño de la masa retroperitoneal residual se asoció con la necesidad de cirugías concomitantes. Conclusiones La LRP-PC es una cirugía de alto nivel de complejidad que se asocia a complicaciones mayores y a la necesidad de cirugías concomitantes. Esta cohorte de pacientes muestra desenlaces similares a los descritos en la literatura, recalcando el hecho de que esta cirugía, debería ser realizada en centros de referencia de manejo del cáncer.

Objective The purpose was to describe complications and concomitant surgeries in PC-RPLND in a Referal cancer center. Methods Data were collected from a retrospective cohort of patients diagnosed with a germ cell tumor of testicular origin who had received chemotherapy and they were diagnosed with retroperitoneal residual tumor and underwent PC-RPLND in a single cancer referral center during 12 years. Results PC-RPLND was performed in 64 patients. The mean age at moment of surgery was 28.1 years (18-47 years). The mean size of the retroperitoneal residual mass was 6.7 (1 - 28 cm). The average hospital stay was 7.9 days (range 1-99 day), the rate of additional surgeries was 20%. The major complication rate was 7.8%. Seminoma histology in testicular tumor was associated with increased bleeding; the size of the residual retroperitoneal mass was associated with the need of concomitant surgeries. Conclusion PC-RPLND is a complex surgery that is associated with major complications and the need of concomitant surgeries. This research shows similar outcomes previously described in the literature highlighting the fact that this surgery should be performed in reference cancer treatment centers.

Enfermedad Mínima Residual en leucemia: rompiendo el paradigma de remisión completa / Residual minimal disease: breaking the paradigm of complete remission

Las malignidades hematológicas constituyen un grupo heterogéneo de condiciones. La enfermedad mínima residual (EMR) hace referencia a la presencia de enfermedad maligna hematológica, en pacientes que se encuentran en remisión según análisis convencionales. La EMR ha mostrado tener importancia pronóstica en condiciones como: leucemia mieloide aguda, leucemia mieloide crónica, mieloma múltiple, y en leucemia linfoide aguda y crónica. La detección ultrasensible de este estado podría permitir una mejor estratificación del riesgo y de igual forma abrir oportunidades para intervenciones terapéuticas tempranas. En el siguiente artículo se realiza una breve revisión acerca de la importancia pronóstica de la EMR en diferentes malignidades hematológicas(AU)

Hematological malignancies constitute a heterogeneous group of conditions. Residual minimal disease (RMS) refers to the presence of haematological malignancy in patients who are in remission if conventional pathological analyzes are used. RMS has been shown to have prognostic significance in conditions such as: acute myeloid leukemia, chronic myeloid leukemia, multiple myeloma, and acute and chronic lymphoblastic leukemia. Ultrasensitive detection of this condition could allow a better risk stratification and open opportunities for early therapeutic interventions. In the following article there will be a brief review about the prognostic importance of RMS in different hematologic malignancies(AU)

Eventos adversos y complicaciones del tratamiento antineoplásico administrados durante la infancia / Adverse events and complications of antineoplastic treatment administered during childhood

El cáncer infantil es una enfermedad crónica potencialmente mortal, la cual representa un gran impacto no solo para los pacientes, sino para su familia. El niño con cáncer debe enfrentarse al impacto emocional, físico, social, psicológico y a los efectos de la enfermedad y su tratamiento. Se considera que uno de cada 640 adultos jóvenes entre las edades de 20 y 39 años presentaron cáncer en su infancia, esto sumado al aumento de sobrevida debido a los tratamientos actuales, hace que las complicaciones que se puedan presentar en el tratamiento o por su enfermedad sean un marcador de morbimortalidad a largo plazo. Por tal motivo, el niño con cáncer debe hacer frente a los cambios adquiridos y a las complicaciones de la enfermedad y su tratamiento. Todos estos factores pueden poner en peligro la calidad de vida del niño con diagnóstico de cáncer y hacer más difícil el cumplimiento del régimen de terapia antineoplásica propuesto. El objetivo de este artículo es hacer una revisión de las principales complicaciones y efectos adversos que pueden ocurrir en pacientes que son sometidos a tratamientos antineoplásicos detallando las complicaciones por sistemas, las complicaciones propias de los medicamentos y los eventos adversos ocurridos por la atención a estos pacientes. MÉD.UIS. 2014;27(3):77-88.

Childhood cancer is a life-threatening chronic disease, which represents a great impact not only for patients, but for their family. The child with cancer must face the emotional, physical, social, and psychological effects of the disease and its treatment impact. It is believed that 1 in every 640 young adults between the ages of 20 and 39 years had cancer in their infancy, this added to increased survival due to current treatments, causes complications that may arise in the treatment or their disease be a marker of long-term morbidity. Therefore children with cancer must face the acquired changes and complications of the disease and its treatment. All these factors can impair the quality of life of children with cancer diagnosis and ensure implementation of the proposed scheme antineoplastic therapy more difficult. The aim of this article is to review major complications and side effects that can occur in patients who are undergoing cancer treatments detailing complications systems, the complications of drugs and adverse events that occurred in the care of these patients. MÉD.UIS. 2014;27(3):77-88.

Análise do PET-CT no estadiamento do câncer epidermoide de cabeça e pescoço / Analysis of PET-CT in the staging of head and neck cancer

Introdução: O carcinoma epidermoide na cabeça e pescoçotem uma recidiva loco-regional em 40% dos casos em dois anos,tornando necessário o seguimento convencional e por meio deexames de imagens, somando-se a técnica do 18F-FDG-PET.Objetivo: Demonstrar os primeiros dois anos de indicações eresultados da PET-CT em uma instituição pública. Método: Estudoretrospectivo de 50 exames de julho de 2009 a junho de 2012,realizados consecutivamente em 49 pacientes com carcinomaepidermoide das vias aerodigestivas superiores de estádiosclínicos I (4,1%), II (10,2%), III (32,7%) e IV (53%). Resultados:Em 12 casos, o exame foi realizado durante o estadiamento inicial.Em quatro casos, a PET foi realizado por tumor primário oculto naapresentação inicial. A PET-CT foi realizada pós-tratamento em31 casos, sendo que houve mudança de estádio clínico em 12desses pacientes após a realização da PET-CT. Foram realizadosdois exames em pacientes sob cuidados paliativos com sobrevidasuperior à esperada, sendo um diagnosticado sem doença e outrocom segunda lesão. Conclusão: O diagnóstico e estadiamento docâncer na cabeça e pescoço fazem-se por meio de exame diretocom biópsia e exame histológico. Exames de imagem metabólicose anatômicos - PET-CT - auxiliam, especialmente, no diagnósticodas recidivas loco-regionais.

Levels of CEA and Ca 19 - 9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers / Níveis de CEA e Ca 19 - 9 em soro e cavidade peritoneal em pacientes com câncer do estômago e pâncreas

PURPOSE: Tumor markers are substances found in blood and other biological fluids if tumor is present in the body. They can be produced by tumor itself or can be results of cancer - body relation. They may be used in the follow-up of cancer patients to identify tumor recurrence. Pre-treatment levels have prognostic tool and could signalize persistence of minimal residual disease despite radical surgery. METHODS: We operated on 52 patients with upper GI malignancy (32 with gastric cancer and 20 with pancreatic cancer). Blood samples were taken before surgery and peritoneal samples immediately after laparotomy before any manipulation with tumor. All samples were examined by standard biochemical technique and the level was compared with a stage of the disease. RESULTS: Patients suffering from gastric carcinoma of stage I and II had higher level of both markers in sera then in the peritoneal cavity, however most of them were within physiological range. Patients in stage III and IV had average marker levels in the peritoneal cavity higher than in sera. Number of positive findings was increasing according to the stage of the disease. The peritoneal levels of both markers varied extremely in higher stages. In patients suffering from pancreatic carcinoma the CEA levels both in sera and peritoneal cavity were parallel but peritoneal levels were slightly higher in stages III and IV. Ca 19 - 9 was more sensitive for pancreatic cancer. The percentage of positive findings was higher in sera but the level of Ca 19 - 9 was higher in the peritoneal cavity. The number of positive findings again correlated with the stage of the disease. CONCLUSIONS: Levels of tumor markers in sera could signalize inoperability of tumor (Ca 19 - 9 in cases of pancreatic carcinoma); peritoneal levels could predict R1 resection especially in gastric cancer patients and risk of early peritoneal recurrence of the disease. Difference between the levels in the peritoneum and sera may signalize the route of dissemination (hematogenous and intraperitoneal).

OBJETIVO: Os marcadores tumorais são substâncias encontradas no sangue e outros fluidos biológicos em pacientes com doenças oncológicas. São produzidos pelo próprio tumor ou ser resultado da interação entre o tumor e o organismo. Podem ser usados no seguimento de pacientes com câncer para identificar recidiva tumoral. Os níveis pré-tratamento têm valor prognóstico e podem sinalizar persistência de doença residual mínima após cirurgia radical.. MÉTODOS: Foram operados 52 pacientes com tumores do trato gastroinstestinal superior (32 com câncer do estômago e 20 do pâncreas). Amostras sanguineas foram colhidas no préoperatório e amostras peritoneais imediatamente após a laparotomia, antes de qualquer manipulação do tumor. Todas as amostras foram examinadas bioquímicamente e os resultados foram comparados entre si e em face ao progresso da doença. RESULTADOS: Os pacientes com câncer de estômago nos estadios I e II apresentaram níveis sanguineos mais elevados de ambos os marcadores tumorais do que no peritônio, mas a maioria dos valores encontrava-se dentro dos limites fisiológicos. Já nos estadios III e IV os níveis dos marcadores tumorais foram mais elevados no peritônio do que no sangue. O número de exames positivos aumentou de acordo com o estadio da doença. Nos estádios avançados, observou-se elevada variabilidade nos níveis de ambos os marcadores analisados no peritônio. Os doentes com carcinoma de pâncreas tiveram níveis de CEA semelhantes no sangue e no peritônio, mas os níveis peritoneais foram ligeiramente mais elevados nos estadios III e IV. Ca 19 - 9 foi muito mais sensível para o câncer do pâncreas. A porcentagem de exames positivos foi mais elevada no sangue, mas o níveis do Ca19-9 foram mais elevados no peritônio.A porcentagem de exames positivos também teve correlação com o estadio da doença. CONCLUSÕES: Os níveis de marcadores tumorais no sangue podem indicar inoperabilidade do tumor. No peritônio podem indicar o tipo de ressecção, especialmente nos doentes com câncer gástrico, e o risco de recidiva peritoneal precoce. A diferença entre os níveis no peritônio e sangue podem sinalizar a via de disseminação, hematogênica ou intra-peritoneal.

Clinical observation on loop electrosurgical excision procefure and colposcope in diagnosis and treatment for cevical intraepithelial neoplasia / 中国基层医药

Objective To study the effect of loop electrosurgical excision procedure(LEEP) and colposcope in diagnosis and treatment for cervical intraepithelial neoplasia.Methods A prospective randomized control trail was performed in 116 cervical in traepithelial neoplasia(CIN) patients wederwent LEEP.In 60 patients in the study group,the colposcope definitude locality and distributing of CIN before LEEP.In 56 patients the control group,spread Iodin solution on cervical definitude locality and distributing of CIN before LEEP.Then,follow-up was performed postoperatively in 1,3,6 months respectively.The operation time,the bleeding volume,the rate of residual were compared between the two groups,follow-up CIN.Results The rate of residual in the study group (4/60)6.67 ％ was lower than that in the control group(10/56) 17.86％.There was statistical difference between them(P =0.018).There was no statistical difference between them in the operation time and the bleeding volume( P ＞ 0.05 ).Conclusion With colposcope,Can reduce the rate of residual.

Análise da margem cirúrgica proximal do estômago em pacientes submetidos à gastrectomia subtotal por adenocarcinoma / Proximal gastric margin analysis following subtotal gastrectomy for adenocarcinoma

RACIONAL: A gastrectomia subtotal atualmente é considerada padrão ouro no tratamento da neoplasia gástrica do terço médio e distal. No entanto, foi demonstrado que a ocorrência de neoplasia residual na margem cirúrgica proximal está associada à redução da sobrevida. OBJETIVOS: analisar a margem cirúrgica proximal no exame anátomo-patológico de pacientes submetidos à gastrectomia subtotal por adenocarcinoma gástrico e identificar os fatores relacionados com o acometimento neoplásico dessa margem. MÉTODOS: No período entre janeiro de 1998 e dezembro de 2007 foram revisados os prontuários dos pacientes submetidos à gastrectomia subtotal devido a adenocarcinoma gástrico do terço médio e distal. Os pacientes foram analisados quanto à idade, sexo, classificação de Lauren, classificação de Borrmann, maior diâmetro da lesão, localização da lesão no estômago, clínico e presença de invasão angiolinfática. Foi realizada análise univariada desses dados em relação ao acometimento da margem proximal do estômago no exame anátomo-patológico. RESULTADOS: Foram analisados 104 casos: 34 do sexo feminino e 70 do sexo masculino com idade média de 57±13 anos. Doze pacientes (12,3 por cento) apresentaram acometimento da margem proximal. A análise univariada entre os fatores analisados e o acometimento neoplásico da margem proximal demonstrou associação somente em relação à classificação de Borrmann. CONCLUSÃO: A classificação macroscópica de Borrmann, especialmente nos estágios III e IV, está relacionada à presença de acometimento da margem proximal nos casos de adenocarcinoma gástrico dos terços médio e distal submetidos a tratamento com gastrectomia subtotal.

BACKGROUND: Subtotal gastrectomy is considered the gold standard treatment for gastric neoplasms localized in the distal and medial thirds of the stomach. Nevertheless, it has been shown that residual neoplasm into the proximal margin is associated to worse prognosis. AIM: To identify factors related to residual neoplasm into the proximal margin determined on pathology examination of patients subjected(Submitted) to subtotal gastrectomy for gastric adenocarcinoma. METHODS: The charts of the patients subjected(Submitted) to subtotal gastrectomy due to gastric adenocarcinoma of the distal and medial thirds were reviewed from January 1998 to December 2007. It was recorded data referred to age, sex, Lauren and Borrmann staging, neoplasm diameter, localization inside the stomach, TNM staging and angiolymphatic invasion. These data were submitted to univariate analysis in relation to residual neoplasm into the proximal margin. RESULTS: A hundread and four cases were included: 34 females and 70 males. The median age was 57±13 years. Twelve patients (12.3 percent) presented residual neoplasm into the proximal margin. The univariate analysis showed association between only the Borrmann staging and the residual neoplasm. CONCLUSION: Borrmann staging is associated to residual neoplasm into the proximal margin in patients subjected(Submitted) to subtotal gastrectomy for medial and distal thirds gastric adenocarcinoma.

Avaliação do tecido glandular e neoplasia residual no retalho cutâneo após mastectomia com preservação de pele por câncer de mama / Evaluation of glandular tissue and residual tumor in the skin flap after slin-parking mastectomies due breast cancer

O objetivo do trabalho foi avaliar a prevalência de tecido glandular e neoplasia residual no retalho cutâneo de pacientes submetidas à mastectomia com preservação de pele (MPP). Quarenta e duas mulheres portadoras de carcinoma de mama, estadio 0 a III, foram submetidas à MPP entre junho de 2003 e janeiro de 2004. Antes da cirurgia, foram desenhadas duas linhas na pele da mama, representando as incisões da MPP e da mastectomia convencional. Após a cirurgia, o retalho cutâneo que permaneceria após a MPP foi retirado. Neste, foram avaliadas a presença de tecido glandular mamário, através da identificação de unidades ducto tubulares alveolares (UDTL), assim como, a presença de neoplasia residual, por microscopia óptica. Estes dados foram correlacionados com outros parâmetros clínicos e patológicos, através de teste exato de Fisher e curva ROC. Em 25/42 (59,5%) dos casos havia UDTL remanescente, associada significativamente com espessura do retalho cutâneo > 5 mm. Em 4/42 das pacientes havia neoplasia residual na pele, associada à espessura > 5mm e presença de UDTL. A curva ROC mostrou que conforme a espessura do retalho cutâneo diminui, também diminui a prevalência de UDTL. Foi concluído que alta prevalência de UDTL e de neoplasia residual estiveram associadas a espessuras de retalhos cutâneos > que 5 mm.

The objective of the study was to evaluate the prevalence of glandular tissue and residual tumor in the skin flap after skin-sparing mastectomies (SSM). Forty-two breast cancer female patients, stage 0 - III, without clinical skin involvement, underwent SSM from June 2003 to January 2004. Before surgery, two lines were drawn on the breast skin, representing SSM and conventional mastectomy incisions. After surgery, the skin flap that would remain after SSM was removed and immediate breast reconstruction was begun. The presence and amount of remaining glandular breast tissues were histologically evaluated in the skin flap, identifying terminal duct-lobular units (TDLU) under an optical microscope, as well as the presence of residual disease. These data were correlated with other clinical and pathological parameters, using the Fisher exact test and ROC curve. The prevalence of residual breast tissue in the sample was 59,5% (25/42) and the presence of TDLU was significantly associated with skin flaps thicker than 5mm. Residual disease was found in 9,5% (4/42) of the women and associated with skin flaps > 5mm thick and presence of TDLU. The ROC curve showed that, as skin flaps reduces in thickness, the presence of TDLU also decreases. It was concluded that a high prevalence of glandular breast tissue and residual disease in the skin flap were associated with skin flaps thickness > 5mm.